453 related articles for article (PubMed ID: 25877780)
1. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
[TBL] [Abstract][Full Text] [Related]
4. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
5. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
6. From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
Mostinski Y; Heynen GJJE; López-Alberca MP; Paul J; Miksche S; Radetzki S; Schaller D; Shanina E; Seyffarth C; Kolomeets Y; Ziebart N; de Schryver J; Oestreich S; Neuenschwander M; Roske Y; Heinemann U; Rademacher C; Volkamer A; von Kries JP; Birchmeier W; Nazaré M
J Med Chem; 2020 Dec; 63(23):14780-14804. PubMed ID: 33210922
[TBL] [Abstract][Full Text] [Related]
7. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Wang WL; Chen XY; Gao Y; Gao LX; Sheng L; Zhu J; Xu L; Ding ZZ; Zhang C; Li JY; Li J; Zhou YB
Bioorg Med Chem Lett; 2017 Dec; 27(23):5154-5157. PubMed ID: 29100798
[TBL] [Abstract][Full Text] [Related]
8. Identification of demethylincisterol A
Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
[TBL] [Abstract][Full Text] [Related]
9. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel triazoloquinazolinone derivatives as SHP2 protein inhibitors.
Luo R; Wang Z; Luo D; Qin Y; Zhao C; Yang D; Lu T; Zhou Z; Huang Z
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2170-2182. PubMed ID: 34749564
[TBL] [Abstract][Full Text] [Related]
11. Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
Lee YJ; Song H; Yoon YJ; Park SJ; Kim SY; Cho Han D; Kwon BM
Biochem Pharmacol; 2020 May; 175():113920. PubMed ID: 32201212
[TBL] [Abstract][Full Text] [Related]
12. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Satheeshkumar R; Zhu R; Feng B; Huang C; Gao Y; Gao LX; Shen C; Hou TJ; Xu L; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Med Chem Lett; 2020 Jun; 30(11):127170. PubMed ID: 32273218
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity.
Zhen XL; Yin WH; Tian X; Ma ZJ; Fan SM; Han JR; Liu S
Bioorg Med Chem; 2015 May; 23(10):2562-7. PubMed ID: 25865131
[TBL] [Abstract][Full Text] [Related]
15. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
[TBL] [Abstract][Full Text] [Related]
16. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
17. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
Liu WS; Yang B; Wang RR; Li WY; Ma YC; Zhou L; Du S; Ma Y; Wang RL
Bioorg Chem; 2020 Jul; 100():103875. PubMed ID: 32380342
[TBL] [Abstract][Full Text] [Related]
19. Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2).
Kwon SJ; Ahn D; Yang HM; Kang HJ; Chung SJ
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562835
[TBL] [Abstract][Full Text] [Related]
20. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
